Mustang Bio sells assets and ends lease with AbbVie
Inc., a pharmaceutical company with a market capitalization of $5.67 million, has entered into a definitive agreement with AbbVie (NYSE:ABBV) Bioresearch Center Inc., effectively selling certain ...
AbbVie Inc. (ABBV): Among Lee Munder Capital Group’s Top Stock Picks
We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...
Crain's Chicago Business1d
AbbVie inks another billion-dollar oncology deal
The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...
Xilio Therapeutics Shares Surge Premarket on AbbVie Deal
Xilio Therapeutics shares took flight in premarket trading Wednesday after the clinical-stage biotechnology company formed a potentially lucrative collaboration with AbbVie that includes an equity ...
AbbVie, Xilio Therapeutics Set Collaboration, Option-To-License Agreement
AbbVie and Xilio Therapeutics have inked a collaboration and option-to-license agreement potentially worth more than $2 billion to clinical-stage biotechnology company Xilio.
Healio3d
Upadacitinib, deucravacitinib ‘the top two’ small molecules for psoriatic arthritis
Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...
Managed Healthcare Executive3d
FDA Approves Combination Antibiotic for Complicated Infections
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
Contract Pharma3d
AbbVie’s EMBLAVEO Approved by FDA for Treatment of Complicated Intra-Abdominal Infections
Addresses the significant threat of antimicrobial resistance.